secwatch.observer — SEC 8-K summary
======================================

Issuer:     VOLITIONRX LTD (VNRX)
CIK:        0000093314
Form:       8-K
Filed at:   2023-08-14T23:59:59+00:00
Accession:  0001477932-23-006099
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

VolitionRx submits Breakthrough Device request to FDA for Nu.Q sepsis test; H1 revenue exceeds full-year 2022
--------------------------------------------------------------------------------

- Submitted Breakthrough Device Designation Request to FDA for Nu.Q technology in sepsis in June 2023.
- H1 2023 total revenue $366,000, exceeding full-year 2022 revenue; Nu.Q Vet sales grew five-fold.
- Cash $19.7M at June 30, 2023, vs $10.9M at 2022 year-end; raised $17.6M net in June public offering.
- Expects $13M in milestone payments from Heska and additional non-dilutive Belgian agency funding.
- Centers of Excellence for Nu.Q NETs progressing; first clinical paper submitted for peer review.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/93314/000147793223006099/0001477932-23-006099-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/93314/000147793223006099/vnrx_8k.htm
  HTML page:      https://secwatch.observer/filing/0001477932-23-006099

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer